ABVX: Double Bottom detected on 12 Nov 2026

All prices, scores, and news on this page reflect data available before market open on .

Free example: 1 of 47 setups from the 12 Nov 2026 scan. Subscribers get the full list every trading day by 6 AM ET.

On 12 Nov 2026, our scan flagged ABVX as a double bottom setup scoring 69 out of 98 (Moderate tier), with a 67% win probability based on our historical pattern database and a 0.42 to 1 risk to reward profile from the published levels. This is a swing trade setup: win probability reflects a multi-day swing hold, not an intraday move. At $91.44, the conservative target is $95.77 with a stop at $81.20. A further breakout above resistance near $100.08 offers a larger move if momentum continues past the initial target.

69 of 98
Moderate
67%
Moderate
0.42 : 1
$4.33 to target $10.24 to stop
Swing Trading Plan
Entry
$91.44
$95.77
$81.20
2-7 trading days
Exp. Reward
+$2.28
Exp. Risk
-$1.61

Expected figures are probability-weighted from our historical pattern database; Trade R:R is measured from the entry, target and stop levels.

Current Setup
ABVX is forming a double-bottom reversal pattern with perfect structure score of 15.0. The stock bounced from support at $83.55 and is now trading at $91.44, positioned between key support and resistance at $100.08. Breakout score of 9.75 and volume score of 10.91 indicate moderate confirmation—current volume at 738,764 shares is tracking 83% of the 20-day average. RSI at 51.71 shows neutral momentum without overbought conditions. The pattern quality aggregates to an overall score of 68.66 with 67.18% win probability, suggesting a technically sound setup primed for the measured move target of $95.77.
Stock Context
On November 10, 2026, Abivax presented obefazimod data at the Guggenheim Healthcare Innovation Conference, positioning the drug as a potential new standard in inflammatory bowel disease. The company reported 50% endoscopic remission at the end of maintenance in ulcerative colitis, described as unusually strong across trials. Abivax completed a $920 million public offering in July 2026 and received positive pre-NDA FDA interaction on July 30, 2026. The company holds €402.4 million in cash and short-term investments as of June 30, 2026. Goldman Sachs launched coverage with a Buy rating and $155 target. This recent positive catalysts—FDA interaction, strong Phase 3 data, and bullish analyst initiation—align with the timing of the double-bottom formation and explain why the pattern is emerging now amid biotech sector momentum.
What to Expect
A successful breakout through $100.08 resistance would validate the double-bottom reversal, targeting the conservative measurement of $95.77 initially, with potential for continuation toward $105–110 based on measured move projection. Volume confirmation requires daily volume trending back toward or exceeding the 894,609-share 20-day average; the current 83% relative volume is adequate but not compelling. Invalidation occurs decisively below $83.55 support, where the pattern would fail. With win probability at 67.18%, historical data suggests roughly two-thirds of similar double-bottom setups in biotech resolve in the bullish direction, though execution risk remains material.
Risk Factors
Execution risks remain around regulatory approval, manufacturing, spending, and launch preparation. Abivax reported a net loss of €165.9 million in H1 2026 with R&D expenses of €107.9 million. Wedbush cut its price target to $118 and kept a Neutral rating, arguing that the 2026 NDA filing and possible 2027 approval are already priced in. The stock's 3-month performance of -24.71% shows recent weakness despite positive catalysts, signaling distribution risk. Beta at 0.59 provides some downside protection, but biotech sector volatility at 51.61% over 20 days creates headline risk. An NDA rejection or adverse competitive development could shatter the pattern. Monitor for analyst downgrades or guidance revisions through the planned December investor presentations.
How We Find and Score This Setup
We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading. What the terms mean →
Frequently Asked Questions
Is ABVX a good swing trade?
ABVX scored 69 out of 98 on our double bottom scan, with a 67% historical win probability over a 2-7 trading days hold. Moderate setup based on our systematic scoring.
What is the entry, target, and stop loss for this setup?
The setup's reference price is $91.44, with a conservative target of $95.77 and a stop loss at $81.20.
What would invalidate this double bottom setup?
A close below the stop loss at $81.20 would invalidate the setup and suggest the pattern has failed.
How is the win probability calculated?
Win probability is a calibrated estimate of how similar historical double bottom setups performed over the following 10 trading days, drawn from a database of 370,000+ historical pattern detections across 6,000+ NYSE and NASDAQ stocks.
Market & Sector Regime
Market
Bearish -0.24
-1.0 0 +1.0
Health Care Sector
Bullish 0.89
-1.0 0 +1.0
Overall Score
36 of 40
Exceptional
Pattern Quality
12 of 20
Moderate
Setup
11 of 20
Fair
R/R
10 of 18
Fair
Context
Pattern Quality Score
15 of 15
Exceptional
Structure
10 of 13
Good
Breakout
11 of 12
Exceptional
Volume
Recent Performance
+2.2%
1W
+1.8%
2W
+6.0%
1M
-24.7%
3M
Momentum & Trend
RSI (14)
51.7
Neutral
MACD Histogram
+0.82
Bullish
Bollinger Band Position
77.2%
Upper Zone
Volatility & Risk
20-Day Volatility
0.52
Very High
ATR %
4.1%
Medium
Beta
0.59
Below Mkt
Volume Analysis
Volume Ratio
0.83x
Average
20-Day Avg Vol
895K
shares / day
Current Volume
739K
shares traded
Price Levels
52W High
$148.83
Resistance
$100.08
Target
$95.77
Current
$91.44
Support
$83.55
Stop Loss
$81.20
52W Low
$69.81
Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.